WINTON GROUP Ltd Acquires 5,433 Shares of Insulet Corporation $PODD

WINTON GROUP Ltd grew its holdings in Insulet Corporation (NASDAQ:PODD) by 149.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,065 shares of the medical instruments supplier’s stock after purchasing an additional 5,433 shares during the period. WINTON GROUP Ltd’s holdings in Insulet were worth $1,380,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the business. OneDigital Investment Advisors LLC bought a new position in Insulet in the 2nd quarter worth about $6,741,000. OP Asset Management Ltd bought a new stake in shares of Insulet during the first quarter valued at approximately $1,513,000. SEB Asset Management AB purchased a new stake in shares of Insulet in the first quarter valued at approximately $24,700,000. DNB Asset Management AS boosted its holdings in shares of Insulet by 21.1% in the fourth quarter. DNB Asset Management AS now owns 58,161 shares of the medical instruments supplier’s stock valued at $16,532,000 after purchasing an additional 10,148 shares during the period. Finally, Jupiter Asset Management Ltd. purchased a new stake in shares of Insulet in the fourth quarter valued at approximately $66,644,000.

Analyst Upgrades and Downgrades

PODD has been the topic of several research reports. TD Cowen reduced their price objective on Insulet from $294.00 to $144.00 and set a “hold” rating on the stock in a report on Thursday, August 6th. The Goldman Sachs Group reiterated a “buy” rating and issued a $205.00 target price on shares of Insulet in a report on Wednesday, May 27th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $152.00 price target (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Citigroup raised their price target on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Finally, Bank of America decreased their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a report on Monday, May 18th. Fourteen research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Insulet presently has an average rating of “Hold” and a consensus target price of $195.40.

Insulet Stock Down 2.0%

Insulet stock opened at $131.96 on Friday. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The firm has a market cap of $9.15 billion, a P/E ratio of 24.67, a P/E/G ratio of 1.04 and a beta of 1.08. The business has a fifty day moving average of $152.36 and a two-hundred day moving average of $173.92. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. The business had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The business’s revenue was up 23.5% compared to the same quarter last year. During the same period last year, the business posted $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, analysts forecast that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.